Belite Bio (BLTE) versus Its Rivals Head to Head Comparison

Belite Bio (NASDAQ:BLTE) is one of 986 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its peers? We will compare Belite Bio to similar businesses based on the strength of its dividends, earnings, risk, profitability, valuation, institutional ownership and analyst recommendations.

Risk and Volatility

Belite Bio has a beta of -1.62, indicating that its share price is 262% less volatile than the S&P 500. Comparatively, Belite Bio’s peers have a beta of 0.85, indicating that their average share price is 15% less volatile than the S&P 500.

Profitability

This table compares Belite Bio and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-54.05%	-50.06%
Belite Bio Competitors	-2,086.28%	-226.73%	-28.61%

Insider and Institutional Ownership

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 44.4% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 13.3% of Belite Bio shares are owned by company insiders. Comparatively, 14.4% of shares of all “Pharmaceutical preparations” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Belite Bio and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0	0	7	0	3.00
Belite Bio Competitors	6211	18346	43834	886	2.57

Belite Bio currently has a consensus price target of $44.83, suggesting a potential upside of 34.11%. As a group, “Pharmaceutical preparations” companies have a potential upside of 88.08%. Given Belite Bio’s peers higher possible upside, analysts clearly believe Belite Bio has less favorable growth aspects than its peers.

Earnings and Valuation

This table compares Belite Bio and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Belite Bio	N/A	-$31.63 million	-26.96
Belite Bio Competitors	$1.60 billion	$143.27 million	-4.34

Belite Bio’s peers have higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Summary

Belite Bio peers beat Belite Bio on 8 of the 12 factors compared.

About Belite Bio

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases (STGD1). Its lead product candidate is LBS-008 (Tinlarebant), an orally administered, once-a-day tablet for maintaining the health and integrity of retinal tissues in STGD1 and GA patients. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, type 2 diabetes, and gout, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.